Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on December 27, 2022. The filing addresses the voluntary delisting of the Company's common stock from the Tel Aviv Stock Exchange (TASE).
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and listing status changes.
Material Changes
- Delisting Date: The Company's common stock will be delisted from the TASE on March 22, 2023.
- Last Trading Date: The final day for trading on the TASE is March 20, 2023.
- Continued Listing: The stock will remain listed and traded on the NYSE American.
- Shareholder Action: Holders using Israeli brokers or nominees are advised to contact them regarding the transfer of shares to NYSE American-based accounts.
Outlook, Risks, and Management Commentary
Management highlights several risks associated with the delisting:
- Liquidity and Volatility: Delisting from the TASE may reduce trading volume and liquidity, potentially increasing price volatility and adversely affecting the trading price.
- Capital Raising: Risks exist regarding the ability to raise capital in public or private equity markets to fund R&D and operations.
- Cash Sufficiency: Risks related to the sufficiency of cash, cash equivalents, and short-term deposits.
- Debt Obligations: Risks concerning the ability to make scheduled principal and interest payments or refinance outstanding notes.
Investor Verification Checklist
- Confirm the last trading date on the TASE is March 20, 2023.
- Verify that shares are successfully transferred to a NYSE American-based account if held through an Israeli broker.
- Review recent 10-K or 10-Q filings for current cash balances and debt maturity schedules, as this 8-K does not contain those figures.
- Monitor trading volume and liquidity on the NYSE American post-delisting.